Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties And Methods Of Administering The Same
Patent No. EP3461474 (titled "Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties And Methods Of Administering The Same") was filed by Glaxosmithkline on Aug 31, 2011. The application was issued on Nov 11, 2020.
Patent Summary
Dry powder inhalation device that can be used for treatment of pulmonary and systemic diseases. The device includes a pharmaceutical composition present therein, the pharmaceutical composition comprising a compound which is (6, 11, 16, 17)-6,9-difluoro-17-[(fluoromethyl)thio]carbonyl-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2- furancarboxylate or a solvate thereof.
Patent Family
Patent Oppositions (5)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
EP3461474
- Application Number
- EP18201769A
- Filing Date
- Aug 31, 2011
- Status
- Revoked
- May 27, 2022
- Publication Date
- Nov 11, 2020
- External Links
- Slate, Register , Google Patents